Biliary Tract Cancer Clinical Trials in Los Angeles, California

7 studies are recruiting for biliary tract cancer in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

   Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surg…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA ( Site 0317), Los Angeles, California

   Locations

   55 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06428409 on ClinicalTrials.gov

2. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - Los Angeles, Los Angeles, California

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

3. A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

   The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Los Angeles, California

   Locations

   177 in total

   Run by

   AstraZeneca

   See if you can join NCT07221253 on ClinicalTrials.gov

4. Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

   The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Research Site, Los Angeles, California

   Locations

   269 in total

   Run by

   AstraZeneca

   See if you can join NCT06467357 on ClinicalTrials.gov

5. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

   TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

   Stage

   Phase 2

   Ages

   18 to 130

   Site

   Research Site, Los Angeles, California

   Locations

   96 in total

   Run by

   AstraZeneca

   See if you can join NCT05489211 on ClinicalTrials.gov

6. Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

   Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatme…

   Stage

   Not phased

   Ages

   18 to 99

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT04907643 on ClinicalTrials.gov

7. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

   This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   6 in total

   Run by

   Tanabe Pharma America, Inc.

   See if you can join NCT06943521 on ClinicalTrials.gov